These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1280 related articles for article (PubMed ID: 26561204)
21. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. Rozengurt E; Eibl G World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295 [TBL] [Abstract][Full Text] [Related]
22. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC. Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762 [TBL] [Abstract][Full Text] [Related]
23. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway. Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576 [TBL] [Abstract][Full Text] [Related]
24. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471 [TBL] [Abstract][Full Text] [Related]
25. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ. Kim M; Kim T; Johnson RL; Lim DS Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714 [TBL] [Abstract][Full Text] [Related]
26. Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer. Vahid S; Thaper D; Gibson KF; Bishop JL; Zoubeidi A Sci Rep; 2016 Aug; 6():31842. PubMed ID: 27555231 [TBL] [Abstract][Full Text] [Related]
27. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers. Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856 [TBL] [Abstract][Full Text] [Related]
28. Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury. Konishi T; Schuster RM; Lentsch AB Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G471-G482. PubMed ID: 29351389 [TBL] [Abstract][Full Text] [Related]
29. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443 [TBL] [Abstract][Full Text] [Related]
30. Lats1 and Lats2 regulate YAP and TAZ activity to control the development of mouse Sertoli cells. Abou Nader N; Charrier L; Meisnsohn MC; Banville L; Deffrennes B; St-Jean G; Boerboom D; Zamberlam G; Brind'Amour J; Pépin D; Boyer A FASEB J; 2024 May; 38(9):e23633. PubMed ID: 38690712 [TBL] [Abstract][Full Text] [Related]
31. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway. Jang JW; Kim MK; Bae SC Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552 [TBL] [Abstract][Full Text] [Related]
32. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy. Zhu J; Wu T; Lin Q Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351 [TBL] [Abstract][Full Text] [Related]
33. Hippo signaling promotes JNK-dependent cell migration. Ma X; Wang H; Ji J; Xu W; Sun Y; Li W; Zhang X; Chen J; Xue L Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1934-1939. PubMed ID: 28174264 [TBL] [Abstract][Full Text] [Related]
34. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749 [TBL] [Abstract][Full Text] [Related]
35. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice. Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369 [TBL] [Abstract][Full Text] [Related]
36. TAZ and YAP are frequently activated oncoproteins in sarcomas. Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148 [TBL] [Abstract][Full Text] [Related]
37. Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity. Liu J; Ye L; Li Q; Wu X; Wang B; Ouyang Y; Yuan Z; Li J; Lin C J Pathol; 2018 Jan; 244(1):71-83. PubMed ID: 28991374 [TBL] [Abstract][Full Text] [Related]
38. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling. Hoa L; Kulaberoglu Y; Gundogdu R; Cook D; Mavis M; Gomez M; Gomez V; Hergovich A Cell Signal; 2016 May; 28(5):488-497. PubMed ID: 26898830 [TBL] [Abstract][Full Text] [Related]
39. Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. Kang W; Cheng AS; Yu J; To KF World J Gastroenterol; 2016 Jan; 22(3):1279-88. PubMed ID: 26811664 [TBL] [Abstract][Full Text] [Related]
40. Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer. Yang P; Li Y; Hou J; Wu D; Zeng X; Zeng Z; Zhang J; Xiong Y; Chen L; Yang D; Wan X; Wu Z; Jia L; Liu Q; Lu Q; Zou X; Fang W; Zeng X; Zhou D J Biol Chem; 2024 Jun; 300(6):107309. PubMed ID: 38657867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]